BLUEPRINT
A BLUEPRINT of Haematopoietic Epigenomes
| Coordinatore | STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 39˙635˙628 € |
| EC contributo | 29˙996˙664 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2011-single-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-10-01 - 2016-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
NL (NIJMEGEN) | coordinator | 5˙435˙138.73 |
| 2 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 3˙681˙477.00 |
| 3 |
FUNDACIO PRIVADA PARC CIENTIFIC DE BARCELONA
Organization address
address: Baldiri i Reixac, 10-12 contact info |
ES (BARCELONA) | participant | 1˙880˙000.00 |
| 4 |
EUROPEAN MOLECULAR BIOLOGY LABORATORY
Organization address
address: Meyerhofstrasse 1 contact info |
DE (HEIDELBERG) | participant | 1˙630˙189.60 |
| 5 |
FUNDACIO CENTRE DE REGULACIO GENOMICA
Organization address
address: CARRER DOCTOR AIGUADER 88 contact info |
ES (BARCELONA) | participant | 1˙536˙800.00 |
| 6 |
CELLZOME AG
Organization address
address: MEYERHOFSTRASSE 1 contact info |
DE (HEIDELBERG) | participant | 1˙214˙400.00 |
| 7 |
QUEEN MARY UNIVERSITY OF LONDON
Organization address
address: 327 MILE END ROAD contact info |
UK (LONDON) | participant | 1˙165˙846.00 |
| 8 |
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Organization address
address: Hofgartenstrasse 8 contact info |
DE (MUENCHEN) | participant | 984˙200.00 |
| 9 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 929˙916.40 |
| 10 |
Genomatix Software GmbH
Organization address
address: Bayerstrasse 85a contact info |
DE (Muenchen) | participant | 897˙600.00 |
| 11 |
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Organization address
address: CALLE ROSSELLO 149 PUERTA BJS contact info |
ES (BARCELONA) | participant | 888˙176.80 |
| 12 |
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III
Organization address
address: CALLE MELCHOR FERNANDEZ ALMAGRO 3 contact info |
ES (MADRID) | participant | 710˙600.00 |
| 13 |
ISTITUTO EUROPEO DI ONCOLOGIA SRL
Organization address
address: Via Filodrammatici 10 contact info |
IT (MILANO) | participant | 631˙400.00 |
| 14 |
CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH
Organization address
address: Dr. Ignaz Seipel-Platz 2 contact info |
AT (WIEN) | participant | 614˙265.10 |
| 15 | KOBENHAVNS UNIVERSITET | DK | participant | 600˙000.00 |
| 16 |
Nome Ente NON disponibile
Organization address
address: VIALE BENEDUCE 10 contact info |
IT (CASERTA) | participant | 584˙988.00 |
| 17 |
GENOME RESEARCH LIMITED
Organization address
address: THE GIBBS BUILDING, EUSTON ROAD 215 contact info |
UK (LONDON) | participant | 573˙766.60 |
| 18 |
CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL
Organization address
address: OLSHAUSENSTRASSE 40 contact info |
DE (KIEL) | participant | 557˙840.00 |
| 19 |
DIAGENODE
Organization address
address: RUE DU BOIS SAINT JEAN 3 LIEGE PARK SCIENCE contact info |
BE (SERAING) | participant | 557˙520.00 |
| 20 |
THE BABRAHAM INSTITUTE
Organization address
address: Babraham Hall contact info |
UK (CAMBRIDGE) | participant | 459˙932.50 |
| 21 |
EUROPEAN RESEARCH AND PROJECT OFFICE GMBH
Organization address
address: Science Park 1, Stuhlsatzenhausweg 69 contact info |
DE (SAARBRUECKEN) | participant | 431˙300.00 |
| 22 |
WEIZMANN INSTITUTE OF SCIENCE
Organization address
address: HERZL STREET 234 contact info |
IL (REHOVOT) | participant | 360˙640.80 |
| 23 |
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
Organization address
address: AVENIDA GRAN VIA HOSPITALET 199-203 contact info |
ES (L'HOSPITALET DE LLOBREGAT) | participant | 359˙999.68 |
| 24 |
UNIVERSITAET DES SAARLANDES
Organization address
address: CAMPUS contact info |
DE (SAARBRUECKEN) | participant | 351˙600.00 |
| 25 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 338˙793.80 |
| 26 |
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
Organization address
address: MAULBEERSTRASSE 66 contact info |
CH (BASEL) | participant | 288˙803.24 |
| 27 |
ACADEMISCH ZIEKENHUIS GRONINGEN
Organization address
address: Hanzeplein 1 contact info |
NL (GRONINGEN) | participant | 286˙800.00 |
| 28 |
HALO GENOMICS AB
Organization address
address: DAG HAMMARSKJOLDS VAG 36B contact info |
SE (Uppsala) | participant | 269˙752.80 |
| 29 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 252˙100.00 |
| 30 |
UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA
Organization address
address: Piazzale Aldo Moro 5 contact info |
IT (ROMA) | participant | 224˙880.00 |
| 31 |
BARCELONA SUPERCOMPUTING CENTER - CENTRO NACIONAL DE SUPERCOMPUTACION
Organization address
address: Calle Jordi Girona 31 contact info |
ES (BARCELONA) | participant | 212˙486.40 |
| 32 |
UNIVERSITE DE GENEVE
Organization address
address: Rue du General Dufour 24 contact info |
CH (GENEVE) | participant | 199˙800.00 |
| 33 |
UNIVERSITAET LEIPZIG
Organization address
address: RITTERSTRASSE 26 contact info |
DE (LEIPZIG) | participant | 158˙400.00 |
| 34 |
UNIVERSITAET ULM
Organization address
address: HELMHOLTZSTRASSE 16 contact info |
DE (ULM) | participant | 117˙600.00 |
| 35 |
UNIVERSITAETSKLINIKUM ESSEN
Organization address
address: HUFELANDSTRASSE 55 contact info |
DE (ESSEN) | participant | 115˙200.00 |
| 36 |
SIGOLIS AB
Organization address
address: DAG HAMMARSKJOLDS VAG 58A contact info |
SE (UPPSALA) | participant | 110˙656.80 |
| 37 |
LUNDS UNIVERSITET
Organization address
address: Paradisgatan 5c contact info |
SE (LUND) | participant | 92˙250.00 |
| 38 |
Novartis Forschungsstiftung
Organization address
address: Maulbeerstrasse 66 contact info |
CH (BASEL) | participant | 85˙763.56 |
| 39 |
VIVIA BIOTECH S.L.
Organization address
address: C SANTIAGO GRISOLIA 2 OFICINA 205 contact info |
ES (TRES CANTOS MADRID) | participant | 76˙411.08 |
| 40 |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Organization address
address: Rue Michel -Ange 3 contact info |
FR (PARIS) | participant | 60˙019.20 |
| 41 |
SIENA BIOTECH SPA
Organization address
address: Via Banchi di Sotto 34 contact info |
IT (SIENA) | participant | 40˙248.41 |
| 42 |
AGILENT TECHNOLOGIES SWEDEN AB
Organization address
address: KRONBORGSGRAND 23 contact info |
SE (KISTA) | participant | 21˙601.50 |
| 43 |
THE UNIVERSITY OF EDINBURGH
Organization address
address: OLD COLLEGE, SOUTH BRIDGE contact info |
UK (EDINBURGH) | participant | 7˙500.00 |
| 44 |
CELLZOME GMBH
Organization address
address: MEYERHOFSTRASSE 1 contact info |
DE (HEIDELBERG) | participant | 0.00 |
| 45 |
OXFORD NANOPORE TECHNOLOGIES LTD
Organization address
address: ROBERT ROBINSON AVENUE - OXFORD SCIENCE PARK 4 contact info |
UK (OXFORD) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
In response to the call for a high impact initiative on the human epigenome, the BLUEPRINT Consortium has been formed with the aim of generating at least 100 reference epigenomes and studying them to advance and exploit knowledge of the underlying biological processes and mechanisms in health and disease. BLUEPRINT will focus on distinct types of haematopoietic cells from healthy individuals and on their malignant leukaemic counterparts. Reference epigenomes will be generated by state-of-the-art technologies from highly purified cells for a comprehensive set of epigenetic marks in accordance with quality standards set by IHEC. This resource-generating activity will be conducted at dedicated centres to be complemented by confederated hypothesis-driven research into blood-based diseases, including common leukaemias and autoimmune disease (T1D), by epigenetic targets and compound identification, and by discovery and validation of epigenetic markers for diagnostic use. By focussing on 100 samples of known genetic variation BLUEPRINT will complete an epigenome-wide association study, maximizing the biomedical relevance of the reference epigenomes. Key to the success of BLUEPRINT will be the integration with other data sources (i.e. ICGC, 1000 genomes and ENCODE), comprehensive bioinformatic analysis, and user-friendly dissemination to the wider scientific community. The involvement of innovative companies will energize epigenomic research in the private sector by creating new targets for compounds and the development of smart technologies for better diagnostic tests. BLUEPRINT will outreach through a network of associated members and form critical alliances with leading networks in genomics and epigenomics within Europe and worldwide. Through its interdisciplinarity and scientific excellence combined with its strong commitment to networking, training and communication BLUEPRINT strives to become the cornerstone of the EU contribution to IHEC.
Introduzione (Teaser)
A major EU research initiative is collecting data on how genes are activated or repressed in healthy and diseased cells of the blood system. Results of these analysis are expected to provide novel entrypoints for development of therapies for blood related disorders.
Descrizione progetto (Article)
Organism development, disease, damage and a host of environmental factors, including stress and diet, cause changes in packaging of the DNA in the nucleus of a cell. These so called epigenetic alterations are not actual modifications in the genetic code itself but involve the addition of chemical groups to proteins involved in DNA organization. Aberrant placement of these is associated with diseases such as cancer and diabetes.
Forty-one European universities, research institutes and industrial representatives have come together to chart these epigenetic modification in the project 'A blueprint of haematopoietic epigenomes' (http://www.blueprint-epigenome.eu (BLUEPRINT)) . Researchers are generating 100 reference epigenomes of blood cells to identify markers or indicators of changes heralding stages of disease. The scientists have already prepared and released data of 25 full healthy epigenomes from different blood cell types.In addition, another 26 are close to completion and a a further 60 in the pipeline.
To register the genetic basis of disease development, healthy haematopoietic (progenitor) cells are being compared with their malignant cancer counterparts. They include epigenomes from acute myeloid leukaemia and chronic lymphocytic leukemia. Epigenomes are also being generated from cells treated with known and new compounds in order to understand how targeted therapy changes the epigenomic structure.
The work has already led to the identification of several new epigenetic modulators involved in tumour development. Working with two specific compounds that silence the expression of genes that suppress malignancy, the researchers have patented a new approach for inhibitor identification.
BLUEPRINT's Data Coordination Centre is responsible for the storage and distribution of the considerable amounts of data generated. Partners have developed a common data coordination and analysis strategy as well as frameworks for controlled data access. Besides analysing the epigenomic maps within the consortium, BLUEPRINT makes them immediately available to the scientific community to allow optimal usage of the generated datasets.
Apart from utilizing existing methodologies, smart technologies for better diagnostic tests and miniaturisation of the entire analysis pipeline are being developed. They will reduce the need for huge quantities of cells and allow using epigenomic analysis in a clinical setting.
Together, BLUEPRINT deliverables are uncovering key facts in the epigenetics arena for new diagnostics and prognostics. This new area of personalised medicine will transform European healthcare delivery.